Horizon Therapeutics' Daxdilimab Trial Falls Short on Primary Endpoint
- July 23rd, 2023
- 269 views
Horizon Therapeutics plc (Nasdaq: HZNP) reported disappointing results from its Phase 2 clinical trial for daxdilimab in the treatment of systemic lupus erythematosus (SLE), the most common type of lupus. The trial did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which measured low SLE disease activity.
However, the company reported numerical differences in other endpoints and stated that there were no safety concerns. Horizon Therapeutics remains committed to assessing the full dataset. The company's daxdilimab trials in alopecia areata, discoid lupus erythematosus, and lupus nephritis are still ongoing.
Following the announcement, $HZNP declined by $1.18 (-1.17%) to $100.00 in after-hours trading on Friday.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login